Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Iodine-131-labeled silk fibroin microspheres** are biodegradable radiopharmaceutical microspheres developed experimentally for transarterial radioembolization of hepatocellular carcinoma. The product consists of genipin-crosslinked silk fibroin microspheres, derived from silkworm-cocoon fibroin and radiolabeled with iodine-131 using chloramine-T chemistry. Following intra-arterial hepatic administration, the approximately 11 micrometer microspheres embolize tumor-feeding hepatic arterial vessels while iodine-131 delivers localized internal radiation to liver tumor tissue. In a rat hepatocellular carcinoma model, the material showed favorable tumor-growth inhibition, biodistribution, biodegradability, hemocompatibility, and low cytotoxicity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35507826/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iodine-131-labeled silk fibroin microspheres.